Comparative Pharmacology
Head-to-head clinical analysis: VITRASERT versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITRASERT versus VITRAVENE PRESERVATIVE FREE.
VITRASERT vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Antiviral
Antiviral